Epidemiology of SARS-CoV-2 infection and SARS-CoV-2 positive hospital admissions among children in South Africa.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
01 2022
Historique:
received: 14 09 2021
accepted: 15 09 2021
pubmed: 20 11 2021
medline: 5 1 2022
entrez: 19 11 2021
Statut: ppublish

Résumé

We describe epidemiology and outcomes of confirmed SARS-CoV-2 infection and positive admissions among children <18 years in South Africa, an upper-middle income setting with high inequality. Laboratory and hospital COVID-19 surveillance data, 28 January - 19 September 2020 was used. Testing rates were calculated as number of tested for SARS-CoV-2 divided by population at risk; test positivity rates were calculated as positive tests divided by total number of tests. In-hospital case fatality ratio (CFR) was calculated based on hospitalized positive admissions with outcome data who died in-hospital and whose death was judged SARS-CoV-2 related by attending physician. 315 570 children aged <18 years were tested for SARS-CoV-2; representing 8.9% of all 3 548 738 tests and 1.6% of all children in the country. Of children tested, 46 137 (14.6%) were positive. Children made up 2.9% (n = 2007) of all SARS-CoV-2 positive admissions to sentinel hospitals. Among children, 47 died (2.6% case-fatality). In-hospital deaths were associated with male sex [adjusted odds ratio (aOR) 2.18 (95% confidence intervals [CI] 1.08-4.40)] vs female; age <1 year [aOR 4.11 (95% CI 1.08-15.54)], age 10-14 years [aOR 4.20 (95% CI1.07-16.44)], age 15-17 years [aOR 4.86 (95% 1.28-18.51)] vs age 1-4 years; admission to a public hospital [aOR 5.07(95% 2.01-12.76)] vs private hospital and ≥1 underlying conditions [aOR 12.09 (95% CI 4.19-34.89)] vs none. Children with underlying conditions were at greater risk of severe SARS-CoV-2 outcomes. Children > 10 years, those in certain provinces and those with underlying conditions should be considered for increased testing and vaccination.

Identifiants

pubmed: 34796674
doi: 10.1111/irv.12916
pmc: PMC9664941
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-47

Subventions

Organisme : Medical Research Council
ID : MR/V028782/1
Pays : United Kingdom
Organisme : National Department of Health, Republic of South Africa

Informations de copyright

© 2021 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.

Références

Eur J Pediatr. 2020 Jul;179(7):1029-1046
pubmed: 32424745
Asian Pac J Allergy Immunol. 2020 Sep;38(3):170-177
pubmed: 32990448
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1081-1088
pubmed: 32790664
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Paediatr Respir Rev. 2021 Jun;38:51-57
pubmed: 32891582
Commun Dis Intell (2018). 2020 Sep 9;44:
pubmed: 32907528
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
BMC Pediatr. 2020 Sep 1;20(1):410
pubmed: 32873269
Pediatr Pulmonol. 2020 Aug;55(8):1892-1899
pubmed: 32492251
Int J Prev Med. 2020 Jun 19;11:74
pubmed: 32742618
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Front Public Health. 2020 Oct 19;8:504
pubmed: 33194933
Pediatr Pulmonol. 2020 Dec;55(12):3487-3496
pubmed: 32757374
J Clin Virol. 2020 Jul;128:104395
pubmed: 32417675
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
JAMA Pediatr. 2020 Apr 8;:
pubmed: 32267485
JAMA Pediatr. 2020 Oct 1;174(10):e202430
pubmed: 32492092
EClinicalMedicine. 2020 Jun 26;24:100433
pubmed: 32766542
Clin Infect Dis. 2021 Jun 15;72(12):2215-2217
pubmed: 32710743
Trop Med Int Health. 2019 Jul;24(7):862-878
pubmed: 31002201
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
J Microbiol Immunol Infect. 2021 Oct;54(5):839-844
pubmed: 32814650
Clin Infect Dis. 2020 Jul 28;71(15):875-878
pubmed: 32227121
N Engl J Med. 2014 Oct 2;371(14):1344-53
pubmed: 25265493
Pediatrics. 2020 Oct;146(4):
pubmed: 32665373
Tidsskr Nor Laegeforen. 2020 Jun 24;140(11):
pubmed: 32815353
Pediatr Res. 2021 Mar;89(4):733-737
pubmed: 32555539
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Pediatr Pulmonol. 2020 Aug;55(8):2115-2127
pubmed: 32519809
Pediatr Pulmonol. 2020 Oct;55(10):2556-2564
pubmed: 32710693
Infect Drug Resist. 2020 Jul 31;13:2649-2655
pubmed: 32801803
Influenza Other Respir Viruses. 2022 Jan;16(1):34-47
pubmed: 34796674
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1517-1521
pubmed: 33090984
J Med Virol. 2021 Feb;93(2):820-830
pubmed: 32691881
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-1329
pubmed: 32941417
Acta Paediatr. 2020 Jun;109(6):1082-1083
pubmed: 32212348
Indian Pediatr. 2020 Sep 15;57(9):808-810
pubmed: 32651306

Auteurs

Tendesayi Kufa (T)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.

Waasila Jassat (W)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Cheryl Cohen (C)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.

Stefano Tempia (S)

School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
MassGenics, Duluth, Georgia, USA.

Maureen Masha (M)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Nicole Wolter (N)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Sibongile Walaza (S)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Anne von Gottburg (A)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Nelesh P Govender (NP)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Gillian Hunt (G)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Andronica Moipone Shonhiwa (AM)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Joy Ebonwu (J)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Genevie Ntshoe (G)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

Wellington Maruma (W)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Poncho Bapela (P)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Nomathamsanqa Ndhlovu (N)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Hlengani Mathema (H)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Motshabi Modise (M)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Liliwe Shuping (L)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Pinky N Manana (PN)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

David Moore (D)

Department of Pediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.

Ziyaad Dangor (Z)

Department of Pediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.

Charl Verwey (C)

Department of Pediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.

Shabir A Madhi (SA)

South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), Faculty of Health Science Johannesburg, University of the Witwatersrand, Johannesburg, South Africa.
Department of Science/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Science Johannesburg, University of the Witwatersrand, Johannesburg, South Africa.

Haroon Saloojee (H)

Department of Pediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.

Heather J Zar (HJ)

Dept of Paediatrics and Child Health, Red Cross Children's Hospital, and SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.

Lucille Blumberg (L)

National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH